The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | Next-generation BTK inhibitors and their value in CLL
Anthony Mato, MD, MSCE, from the Hospital of the University of Pennsylvania, Philadelphia, PA, talks to us about next-generation BTK inhibitors such as acalabrutinib and their results in clinical trials, but notes that long-term follow-up is still required to assess their effectiveness. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
